Over the past two decades, researchers have learned that DNA inside the cell nucleus naturally folds into a network of ...

Governor Ned Lamont’s State of the State address focused heavily on protecting children and improving their physical and ...

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the launch of ResQ215B, a Phase 2 ...

Usually, enemies in ARC Raiders are pretty keen to fight back, peppering you with bullets or blowing you up with targeted ...

Governor Ned Lamont addressed federal budget cuts and affordability concerns in his State of the State address as lawmakers ...

Discover how Laverdia CA1 (verdinexor) treats canine lymphoma. Learn about the mechanism of action, handling precautions, and ...

Material won a $1.25 million contract from the US Air Force to validate the 3D-printing technology earlier this year. The 18-month project aims to demonstrate how printed, ...

A groundbreaking phase 2 trial explores a novel, chemotherapy-free immunotherapy for relapsed indolent B-cell lymphomas, aiming to enhance patient outcomes.

The study builds on data from an early-stage study which evaluated CD19 CAR-NK cell therapy in combination with the Rituximab ...

Researchers have created the first complete map showing how hundreds of mutations in a key cancer gene affect tumor growth.

Side effects of Lymphir are generally mild to moderate and manageable, with rapid relief from severe itching often observed. Lymphir's availability offers disease control and quality of life ...

FDA proposes MRD-negative and complete response endpoints to fast-track multiple myeloma drug approvals, pushing deeper molecular results over ORR.